false
0001761612
00-0000000
true
0001761612
2024-08-06
2024-08-06
0001761612
us-gaap:CommonStockMember
2024-08-06
2024-08-06
0001761612
bcyc:AmericanDepositarySharesMember
2024-08-06
2024-08-06
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section
13 or 15(d) of the Securities Exchange Act of 1934
August 6, 2024
Date of Report (Date of earliest event reported)
Bicycle Therapeutics plc
(Exact name of registrant as specified in its charter)
England and Wales |
|
001-38916 |
|
Not applicable |
(State or other jurisdiction
of
incorporation) |
|
(Commission
File Number) |
|
(IRS Employer
Identification No.) |
Blocks
A & B, Portway Building, Granta
Park Great Abington, Cambridge United
Kingdom
|
CB21
6GS |
(Address of principal executive offices) |
(Zip Code) |
Registrant’s telephone number, including area code: +44 1223
261503
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b)
of the Act:
Title of each class |
Trading
Symbol (s) |
Name
of each exchange on which registered |
Ordinary shares, nominal value £0.01 per share |
n/a |
The Nasdaq Stock Market LLC* |
American Depositary Shares, each representing one ordinary share, nominal value £0.01 per share |
BCYC |
The Nasdaq Stock Market LLC |
* Not for trading, but only in connection
with the listing of the American Depositary Shares on The Nasdaq Stock Market LLC.
Indicate by check mark whether
the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or
Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging
growth company ¨
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02. |
Results of Operations and Financial Condition |
On August 6, 2024, Bicycle Therapeutics plc issued a press release
announcing financial results for the fiscal quarter ended June 30, 2024 and other business highlights. A copy of the press release
is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The information contained in Item 2.02 in this Current Report
on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities
Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed
incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth
by specific reference in such a filing.
Item 9.01 |
Financial Statements and Exhibits |
(d) Exhibits
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
Date: August 6, 2024 |
BICYCLE THERAPEUTICS PLC |
|
|
|
By: |
/s/ Alethia Young |
|
Name: Alethia Young |
|
Title: Chief Financial Officer |
Exhibit 99.1
Bicycle Therapeutics Reports Recent Business
Progress and Second Quarter 2024 Financial Results
Four abstracts containing data updates across
clinical pipeline accepted for poster presentation at ESMO Congress 2024
Focused R&D pipeline on clinical programs
and research areas that have the highest potential to maximize value creation
Streamlined leadership team to better align
with strategic and pipeline priorities, and enhanced oncology expertise with formation of Clinical Advisory Board
Strengthened balance sheet with gross proceeds
of approximately $555 million from May 2024 private investment in public equity (PIPE) financing
Cash and cash
equivalents of $961.4 million as of June 30, 2024, expected to provide financial runway into 2H 2027
CAMBRIDGE, England & BOSTON, August 6, 2024 – Bicycle
Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary
bicyclic peptide (Bicycle®) technology, today reported recent business progress and financial results for the second quarter
ended June 30, 2024.
“In the second quarter, we continued
to demonstrate the ongoing progress of our pipeline and highlight the emerging differentiated profiles of our Bicycle Toxin Conjugates®
zelenectide pevedotin and BT5528 compared to antibody drug conjugates. As we enter the second half of the year, we look forward to sharing
the first set of data updates from our clinical programs at the upcoming ESMO Congress,” said Kevin Lee, Ph.D., CEO of Bicycle Therapeutics.
“Additionally, I am honored to welcome renowned oncology experts from around the world to our Clinical Advisory Board. Their
advice and counsel will be critical as we work to develop therapies that can help patients live longer and live well.”
Dr. Lee continued: “Bicycle Therapeutics also significantly
strengthened our balance sheet in the second quarter through the support of leading healthcare investors. Moreover, we have prioritized
our pipeline and streamlined our leadership team to enable us to focus on the clinical programs and research areas that we believe have
the highest potential for value creation and align with our strategy to support the long-term growth of our company.”
Second Quarter 2024 and Recent Events
| · | Four abstracts accepted for poster presentation at the European Society
for Medical Oncology (ESMO) Congress 2024 being held September 13-17 in Barcelona. Bicycle Therapeutics will present four abstracts
containing updated clinical data for zelenectide pevedotin (formerly BT8009) in metastatic urothelial cancer (mUC), BT5528 in advanced
solid tumors such as mUC and ovarian, and BT7480 in advanced solid tumors. |
In June, the company presented two
abstracts at the 2024 American Society for Clinical Oncology (ASCO) Annual Meeting outlining clinical pharmacokinetics of
Bicycle® Toxin Conjugate (BTC®) molecules zelenectide pevedotin and BT5528 compared to antibody drug
conjugate enfortumab vedotin and evaluating the emerging safety profile of both BTC molecules, along with an overview of the
company’s ongoing Phase 2/3 Duravelo-2 registrational trial of zelenectide pevedotin in mUC.
| · | Focused research and development (R&D) pipeline on clinical programs
and research areas that the company believes have the highest potential to maximize value creation. Activities include: |
| o | Prioritizing the clinical development of zelenectide pevedotin and BT5528 in multiple tumor types. |
| o | Focusing near-term research efforts on advancing the company’s Bicycle Radionuclide Conjugate (BRC™) pipeline and the discovery of next-generation
BTC molecules. |
| o | Except for BT7480, exploring innovative ways to continue development of the company’s immuno-oncology portfolio, including Bicycle
Tumor-targeted Immune Cell Agonist® (Bicycle TICA®) molecules, through collaboration. |
| · | Streamlined leadership team to better align with strategic and pipeline
priorities. |
| o | Michael Skynner, Ph.D., chief technology officer, has assumed leadership of Bicycle Therapeutics’ discovery research
team, and all discovery research activities will be consolidated and moved to the company’s headquarters in Cambridge, UK. |
| o | Jennifer Perry, Pharm.D., promoted to chief strategy officer and head of commercial. Since joining Bicycle Therapeutics in
August 2022, Ms. Perry has been instrumental in establishing and growing Bicycle Therapeutics’ commercial organization.
In this expanded role, she will oversee the company’s corporate and end-to-end portfolio strategy while also fulfilling her existing
commercial responsibilities. Ms. Perry has more than 20 years of experience in pharma and biotech, with 15 years in oncology. Her
experience spans commercial and medical roles with a focus on go-to-market strategies for launching oncology medicines at GSK, Tesaro,
TG Therapeutics and Pharmacyclics. |
| o | Nick Keen, Ph.D., chief scientific officer, is transitioning to an advisor role with the company as a distinguished fellow,
where he will advise the company as needed. The company also hired Eric Westin, M.D., former vice president of clinical development
and translational sciences at ImmunoGen, to an advisor role with the company as a distinguished fellow to help refine the company’s
translational and clinical strategy. |
| · | Formed new Clinical Advisory Board with distinguished global
oncology experts to support the advancement of clinical oncology programs. The company expects that the advisors will provide
invaluable guidance and insights for the global clinical development of the company’s clinical programs. Inaugural members
include: |
| o | Charles Swanton, M.D., Ph.D., FRS, FMedSci, FRCP, is the chair of Bicycle Therapeutics’ Clinical Advisory Board and Scientific
Advisory Board. He leads the Cancer Evolution and Genome Instability Laboratory at the Francis Crick Institute in London. Dr. Swanton’s
research is focused on how tumors evolve over space and time, and he has authored over 250 papers developing an understanding of branching
evolutionary histories of solid tumors, processes that drive cancer cell-to-cell variation, and the impact of cancer diversity on effective
immune surveillance and clinical outcome. |
| o | Toni K. Choueiri, M.D., is the director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber Cancer Institute
and the Jerome and Nancy Kohlberg Chair and Professor of Medicine at Harvard Medical School. Dr. Choueiri and colleagues have made
seminal observations that have defined and evolved the treatment of kidney cancer and led to the approval of several therapies. He has
over 800 PubMed-indexed publications and is the lead investigator of multiple national and international Phase 1-3 trials in GU cancers. |
| o | Sherene Loi, MBBS (Hons), Ph.D., FRACP, FAHMS, is a medical oncologist specialized in breast cancer treatment and a clinician
scientist (lab head) with expertise in genomics, immunology and drug development at the Peter MacCallum Cancer Centre in Melbourne, Australia.
She is recognized internationally as a leading clinician scientist whose work has led to new insights into the breast cancer immunology
field as well as leading international clinical trials in breast cancer immunotherapy. Professor Loi has published over 330 research articles,
co-chairs the International Breast Cancer Study Group and is the Inaugural National Breast Cancer Foundation of Australia Endowed Chair.
In 2021, she received the Australian Prime Minister’s Frank Fenner Prize for Life Scientist of the Year. |
| o | Solange Peters, M.D., Ph.D., is full professor and chair of medical oncology and the chair of the thoracic malignancies program
in the Department of Oncology at the University Hospital of Lausanne in Switzerland. She currently oversees teaching and patient care
in thoracic malignancies at Lausanne University, and her main fields of interest include new biomarker discovery and validation in preclinical
and clinical settings as well as cancer immunotherapy. She is the youngest president of ESMO, serving
for an extended period of 2020-2022. Professor Peters has authored over 500 peer-reviewed manuscripts and book chapters and is associate
editor of the Annals of Oncology, deputy editor of Lung Cancer and serves on the editorial board of several other oncology
journals. She was the deputy editor of the Journal of Thoracic Oncology for 10 years. |
| · | Raised gross proceeds of $555 million in private investment in public
equity (PIPE) financing. The PIPE financing, with participation from leading healthcare investors, is expected to extend the company’s
financial runway into the second half of 2027. The company plans to use the net proceeds of $544.1 million to fund the continued development
of its proprietary pipeline and for other R&D, as well as for general corporate purposes. |
| · | Repaid and voluntarily terminated outstanding debt with Hercules. In
July 2024, Bicycle Therapeutics announced the repayment of its loan with Hercules Capital, Inc., ahead of its 2025 maturity
date, with total payments of $31.9 million, including accrued and unpaid interest, an end-of-term charge and an early repayment fee. |
Second Quarter 2024 Financial Results
| · | Cash and cash equivalents were $961.4 million as of June 30, 2024, compared
to $526.4 million as of December 31, 2023. The increase in cash and cash equivalents is primarily due to net proceeds from the PIPE
financing and share option exercises, offset by cash used in operating activities. |
| · | R&D expenses were $40.1 million for the three months ended
June 30, 2024, compared to $39.7 million for the three months ended June 30, 2023. The increase in expense of $0.4 million was
primarily due to increased clinical program expenses for zelenectide pevedotin development and increased personnel-related expenses, offset
by decreased clinical program expenses for Bicycle TICA® molecule development, decreased discovery, platform and other
expenses and incremental U.K. R&D tax credits. |
| · | General and administrative expenses were $15.9 million for the three
months ended June 30, 2024, compared to $14.8 million for the three months ended June 30, 2023. The increase of $1.1 million
was primarily due to increased personnel-related costs. |
| · | Net loss was $39.8 million, or $(0.77) basic and diluted net loss
per share, for the three months ended June 30, 2024, compared to net loss of $42.6 million or $(1.41) basic and diluted net
loss per share, for three months ended June 30, 2023. |
About Bicycle Therapeutics
Bicycle Therapeutics is a clinical-stage pharmaceutical company
developing a novel class of medicines, referred to as Bicycle® molecules, for diseases that are underserved by existing
therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize
their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycle molecules attractive
candidates for drug development. The company is evaluating zelenectide pevedotin (formerly BT8009), a Bicycle® Toxin
Conjugate (BTC®) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC molecule targeting EphA2, a historically
undruggable target; and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist® (Bicycle TICA®) targeting
Nectin-4 and agonizing CD137, in company-sponsored clinical trials. Additionally, the company is developing Bicycle® Radio
Conjugates (BRC™) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle® technology
to develop therapies for diseases beyond oncology.
Bicycle Therapeutics is headquartered in Cambridge, UK, with
many key functions and members of its leadership team located in Cambridge, Mass. For more information, visit bicycletherapeutics.com.
Forward Looking Statements
This press release may contain forward-looking statements made pursuant
to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such
as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,”
“forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,”
“seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking
statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include,
but are not limited to, statements regarding Bicycle’s anticipated progress across its R&D pipeline and the advancement of its
product candidates, including zelenectide pevedotin, BT5528 and BT7480; the anticipated progression of Bicycle’s clinical trials
and the method and timing of announcement of data from clinical trials and program updates for clinical candidates; Bicycle’s beliefs
regarding the clinical programs and research areas with the highest potential to maximize value creation and the company’s activities
to focus on such programs and areas; the guidance and insights provided by the Clinical Advisory Board; the development of potential radiopharmaceutical
or other product candidates using Bicycle’s technology through various partnerships; the therapeutic potential for Bicycles in oncology
and other applications; and Bicycle’s expected financial runway. Bicycle may not actually achieve the plans, intentions or expectations
disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results
or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result
of various factors, including: uncertainties inherent in research and development and in the initiation, progress and completion of clinical
trials and clinical development of Bicycle’s product candidates; the risk that Bicycle may not realize the intended benefits of
its technology or partnerships; timing of results from clinical trials; whether the outcomes of preclinical studies will be predictive
of clinical trial results; the risk that trials may have unsatisfactory outcomes; potential adverse effects arising from the testing or
use of Bicycle’s product candidates; the risk that Bicycle’s management have not focused the company’s activities on
the clinical programs and research areas with the highest potential to maximize value creation; the risk that the Clinical Advisory Board
does not provide guidance or insights or that such guidance turns out to be deficient; the risk that Bicycle’s projections regarding
its expected cash runway are inaccurate or that its conduct of its business requires more cash than anticipated; and other important factors,
any of which could cause Bicycle’s actual results to differ from those contained in the forward-looking statements, are described
in greater detail in the section entitled “Risk Factors” in Bicycle’s Quarterly Report on Form 10-Q filed with
the Securities and Exchange Commission (SEC) on May 2, 2024, as well as in other filings Bicycle may make with the SEC in the future.
Any forward-looking statements contained in this press release speak only as of the date hereof, and Bicycle expressly disclaims any obligation
to update any forward-looking statements contained herein, whether because of any new information, future events, changed circumstances
or otherwise, except as otherwise required by law.
Bicycle Therapeutics plc
Condensed Consolidated Statements of Operations
and Comprehensive Loss
(In thousands, except share and per share data)
(Unaudited)
| |
Three Months Ended | |
Six Months Ended | |
| |
June 30, | |
June 30, | |
| |
2024 | |
2023 | |
2024 | |
2023 | |
Collaboration revenues | |
$ | 9,361 | |
$ | 11,397 | |
$ | 28,891 | |
$ | 16,293 | |
Operating expenses: | |
| | |
| | |
| | |
| | |
Research and development | |
| 40,059 | |
| 39,720 | |
| 74,923 | |
| 71,931 | |
General and administrative | |
| 15,949 | |
| 14,788 | |
| 32,331 | |
| 29,276 | |
Total operating expenses | |
| 56,008 | |
| 54,508 | |
| 107,254 | |
| 101,207 | |
Loss from operations | |
| (46,647 | ) |
| (43,111 | ) |
| (78,363 | ) |
| (84,914 | ) |
Other income (expense): | |
| | |
| | |
| | |
| | |
Interest income | |
| 7,774 | |
| 812 | |
| 13,398 | |
| 3,741 | |
Interest expense | |
| (824 | ) |
| (821 | ) |
| (1,645 | ) |
| (1,629 | ) |
Total other income (expense), net | |
| 6,950 | |
| (9 | ) |
| 11,753 | |
| 2,112 | |
Net loss before income tax provision | |
| (39,697 | ) |
| (43,120 | ) |
| (66,610 | ) |
| (82,802 | ) |
Provision for (benefit from) income taxes | |
| 115 | |
| (517 | ) |
| (235 | ) |
| (1,135 | ) |
Net loss | |
$ | (39,812 | ) |
$ | (42,603 | ) |
$ | (66,375 | ) |
$ | (81,667 | ) |
Net loss per share, basic and diluted | |
$ | (0.77 | ) |
$ | (1.41 | ) |
$ | (1.40 | ) |
$ | (2.71 | ) |
Weighted average ordinary shares outstanding, basic and diluted | |
| 51,992,034 | |
| 30,191,693 | |
| 47,276,062 | |
| 30,097,234 | |
Condensed Consolidated Balance Sheets Data
(In thousands)
(Unaudited)
| |
June 30, | |
December 31, | |
| |
2024 | |
2023 | |
Cash and cash equivalents | |
$ | 961,364 | |
$ | 526,423 | |
Working capital | |
| 958,645 | |
| 492,331 | |
Total assets | |
| 1,057,355 | |
| 595,344 | |
Total shareholders’ equity | |
| 873,813 | |
| 370,932 | |
Investors:
Stephanie Yao
SVP, Investor Relations and Corporate Communications
ir@bicycletx.com
857-523-8544
Media:
Deborah Elson
Argot Partners
media@bicycletx.com
212-600-1902
v3.24.2.u1
Cover
|
Aug. 06, 2024 |
Document Information [Line Items] |
|
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Aug. 06, 2024
|
Entity File Number |
001-38916
|
Entity Registrant Name |
Bicycle Therapeutics plc
|
Entity Central Index Key |
0001761612
|
Entity Tax Identification Number |
00-0000000
|
Entity Incorporation, State or Country Code |
X0
|
Entity Address, Address Line One |
Blocks
A & B, Portway Building
|
Entity Address, Address Line Two |
Granta
Park Great Abington
|
Entity Address, City or Town |
Cambridge
|
Entity Address, Country |
GB
|
Entity Address, Postal Zip Code |
CB21
6GS
|
City Area Code |
+44
|
Local Phone Number |
1223
261503
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Entity Emerging Growth Company |
false
|
Common Stock [Member] |
|
Document Information [Line Items] |
|
Title of 12(b) Security |
Ordinary shares, nominal value £0.01 per share
|
No Trading Symbol Flag |
true
|
Security Exchange Name |
NASDAQ
|
American Depositary Shares [Member] |
|
Document Information [Line Items] |
|
Title of 12(b) Security |
American Depositary Shares, each representing one ordinary share, nominal value £0.01 per share
|
Trading Symbol |
BCYC
|
Security Exchange Name |
NASDAQ
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionISO 3166-1 alpha-2 country code.
+ References
+ Details
Name: |
dei_EntityAddressCountry |
Namespace Prefix: |
dei_ |
Data Type: |
dei:countryCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true only for a security having no trading symbol.
+ References
+ Details
Name: |
dei_NoTradingSymbolFlag |
Namespace Prefix: |
dei_ |
Data Type: |
dei:trueItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=bcyc_AmericanDepositarySharesMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
Bicycle Therapeutics (NASDAQ:BCYC)
Historical Stock Chart
From Aug 2024 to Sep 2024
Bicycle Therapeutics (NASDAQ:BCYC)
Historical Stock Chart
From Sep 2023 to Sep 2024